TRITON-CM

• Research type

  Research Study

• Full title

  TRITON-CM: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Transthyretin-Mediated Amyloidosis with Cardiomyopathy (ATTR amyloidosis with cardiomyopathy)

• IRAS ID

  1012209

• Contact name

  Joana Radcliffe Stevens

• Contact email

  CRGUKStart-upteam.SM@thermofisher.com

• Sponsor organisation

  Alnylam Pharmaceuticals, Inc.

• Research summary

  Transthyretin-mediated (ATTR) amyloidosis is a rare and serious disease that occurs when too much of a protein called transthyretin (TTR) builds up in the body, including in the heart and nerves. When TTR collects in the heart, the heart muscle becomes thick and stiff, causing the heart to fail. As the disease gets worse, people with heart-related problems may be hospitalized more often and may experience death within 2 to 5 years of diagnosis if not treated.
  Researchers are testing a new type of medicine called nucresiran. Nucresiran is an RNAi medicine. This means that the medicine works with the body to block or slow down the abnormal build-up of TTR protein. By lowering the amount of TTR protein in the body, researchers hope that nucresiran might slow down or stop the disease from getting worse.

• REC name

  North West - Liverpool Central Research Ethics Committee

• REC reference

  25/NW/0162

• Date of REC Opinion

  23 Jul 2025

• REC opinion

  Further Information Favourable Opinion